What to expect in the early weeks of oral weight loss treatment

You're a few weeks in. You're taking the tablet every morning, following the routine, managing the nausea. And you're stepping on the scales expecting to see something - anything - and the number is stubbornly staying where it is.

This is a common concern people raise in the early weeks of oral semaglutide, and it's completely understandable. It's also, in most cases, not a sign that anything is wrong. Here’s why.

The dose you're on right now might not be the dose that drives weight loss

Weight loss tablets work on a gradual step-up schedule. You start at 1.5mg, then move to 4mg, 9mg, and eventually up to a 25mg daily dose.

The starting dose is intentionally low as it allows the body's GLP-1 receptors to adapt gradually, which is what makes the medication tolerable over the long term.¹ Meaningful weight loss generally happens further down the line.

In one of the largest clinical trials of oral semaglutide for weight management, participants were on a titration schedule across the first several months before reaching their maintenance dose.² The meaningful weight loss in the trial data accumulated over time, not in the opening weeks.

Something is happening, even if the scale doesn't show it

One of the first things oral semaglutide changes is usually appetite, and this is one of the expected effects of the medication.

GLP-1 receptor agonists work by mimicking a hormone your gut produces after eating. They slow gastric emptying, reduce appetite signalling in the brain, and increase feelings of fullness.³ When this kicks in, which for most people happens within the first week or two, you'll notice it in specific ways like meals feeling satisfying before you've finished them, the mental pull towards snacking quietening down, and food feeling less urgent than it used to.

These changes happen before the scale moves because weight loss is the knock-on effect of sustained reduced intake over time, not an immediate response to the medication itself. These early effects can come before weight loss, but it varies from person to person.

Water retention and body composition complicate the picture early on

Even when you're losing fat, the scale sometimes doesn't move, and occasionally moves in the wrong direction in the very early weeks.

Dietary changes, altered gut motility, and shifts in fluid balance can all affect what the scales show day to day, independent of what's actually happening to your body composition. Muscle is denser than fat, so if you're also doing any resistance exercise, your measurements may tell a more accurate story than your weight alone.

Weighing yourself at the same time each day reduces the noise. Tracking trends over weeks, not days, is how you actually see what's happening.

What the trial data says about timing

Clinical studies have shown that early weeks are not when the bulk of weight loss occurs, and that weight loss generally increases as the dose goes up and the body adapts.

In the OASIS 4 trial, those on oral semaglutide 25mg lost an average of 16.6% of their body weight over 64 weeks.⁴ The trajectory in GLP-1 trials consistently shows that weight loss gradually accelerated as dose titration progresses, with the steepest reductions occurring in the middle months of treatment.⁴ 

It’s like going to the gym and expecting your ‘gains’ to show by week two, when in reality it can take weeks - or months - of training. Remind yourself at this stage that the process has started, and the results will, over time, follow suit.

When to actually be concerned

Patience is warranted in the early weeks, but there are situations where it's worth a conversation with your clinical team.

If you're several months in, on or near your maintenance dose, following the protocol correctly, and seeing no change at all, then it’s worth having a chat with your clinician. People respond differently to the tablets, and that needs a conversation about whether the current treatment is the right fit or whether adjustments are needed.

If you're struggling to follow the daily routine consistently - missing doses, finding the fasting window difficult to sustain, or experiencing side effects that are making adherence hard - raising that early is also worthwhile. Taking the medication consistently and as prescribed is an important factor in achieving the best chance of success

The numan take

The early weeks of oral semaglutide are an adjustment period, not a results period. Appetite changes are one of the expected early effects, and your side effects are tracking what's expected. The dose you're on at week two is not the dose at which meaningful weight loss occurs. And the trial data shows that the results come, albeit after some time.

References

1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021;46:101102.

2. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–719.

3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.

4. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4): a randomised, double-blind, placebo-controlled, phase 3a trial. N Engl J Med. 2025;393(11):1077–1087.